The promise of telomere length, telomerase activity and its regulation in the translocation-dependent cancer ESFT; clinical challenges and utility

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1792, Issue 4, 2009, Pages 260-274

  Proctor, Andrew ^a   Brownhill, Samantha C ^a   Burchill, Susan A ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

Clinical utility; Ewing's sarcoma family of tumours (ESFT); EWS ETS fusion transcript; Standardisation; Telomerase; Translocation dependent cancer

Indexed keywords

TELOMERASE; TELOMERASE REVERSE TRANSCRIPTASE;

CHROMOSOME SIZE; ENZYME REGULATION; ETS GENE; EWING SARCOMA; EWS GENE; GENE; GENE FUSION; GENE TRANSLOCATION; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; TELOMERE;

ANIMALS; CELL AGING; CELL PROLIFERATION; CELL SURVIVAL; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASM PROTEINS; SARCOMA, EWING'S; TELOMERASE; TELOMERE; TRANSLOCATION, GENETIC;

EID: 64249147752     PISSN: 09254439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbadis.2009.02.011     Document Type: Review

References (232)

1. Burchill S.A., and Cullinane C. Primitive neuroectodermal tumours. In: Cullinane C.B., Burchill S.A., Squire J., Lewis I.J., and O'Leary J. (Eds). Molecular Biology and Pathology of Paediatric Cancer (2003), Oxford University Press, Oxford 171-185
2. Lewis I., Burchill S.A., and Souhami R. Ewing's sarcoma and the Ewing family of tumours. In: Souhami R., Tannock I., Hohenberger P., and Horiot J.-C. (Eds). Oxford Textbook of Oncology vol. 2 (2002), Oxford University Press, Oxford 2539-2551
3. Glass A.G., and Fraumeni Jr. J.F. Epidemiology of bone cancer in children. J. Natl. Cancer Inst. 44 (1970) 187-199
4. Li F.P., Tu J.T., Liu F.S., and Shiang E.L. Rarity of Ewing's sarcoma in China. Lancet 1 (1980) 1255
5. Parkin D.M., Stiller C.A., Draper G.J., and Bieber C.A. The international incidence of childhood cancer. Int. J. Cancer 42 (1988) 511-520
6. Burchill S.A. Molecular abnormalities in Ewing's sarcoma. Expert Rev. Anticancer Ther. 8 (2008) 1675-1687
7. Barker L.M., Pendergrass T.W., Sanders J.E., and Hawkins D.S. Survival after recurrence of Ewing's sarcoma family of tumors. J. Clin. Oncol. 23 (2005) 4354-4362
8. Hunold A., Weddeling N., Paulussen M., Ranft A., Liebscher C., and Jurgens H. Topotecan and cyclophosphamide in patients with refractory or relapsed Ewing tumors. Pediatr. Blood Cancer 47 (2006) 795-800
9. Shankar A.G., Ashley S., Craft A.W., and Pinkerton C.R. Outcome after relapse in an unselected cohort of children and adolescents with Ewing sarcoma. Med. Pediatr. Oncol. 40 (2003) 141-147
10. Wagner L.M., McAllister N., Goldsby R.E., Rausen A.R., McNall-Knapp R.Y., McCarville M.B., and Albritton K. Temozolomide and intravenous irinotecan for treatment of advanced Ewing sarcoma. Pediatr. Blood Cancer 48 (2007) 132-139
11. Desmaze C., Zucman J., Delattre O., Thomas G., and Aurias A. Unicolor and bicolor in situ hybridization in the diagnosis of peripheral neuroepithelioma and related tumors. Genes Chromosomes Cancer 5 (1992) 30-34
12. Peter M., Gilbert E., and Delattre O. A multiplex real-time pcr assay for the detection of gene fusions observed in solid tumors. Lab. Invest. 81 (2001) 905-912
13. Taylor C., Patel K., Jones T., Kiely F., De Stavola B.L., and Sheer D. Diagnosis of Ewing's sarcoma and peripheral neuroectodermal tumour based on the detection of t(11;22) using fluorescence in situ hybridisation. Br. J. Cancer 67 (1993) 128-133
14. May W.A., Gishizky M.L., Lessnick S.L., Lunsford L.B., Lewis B.C., Delattre O., Zucman J., Thomas G., and Denny C.T. Ewing sarcoma 11;22 translocation produces a chimeric transcription factor that requires the DNA-binding domain encoded by FLI1 for transformation. Proc. Natl. Acad. Sci. U. S. A. 90 (1993) 5752-5756
15. Thompson A.D., Teitell M.A., Arvand A., and Denny C.T. Divergent Ewing's sarcoma EWS/ETS fusions confer a common tumorigenic phenotype on NIH3T3 cells. Oncogene 18 (1999) 5506-5513
16. Kovar H., Aryee D.N., Jug G., Henockl C., Schemper M., Delattre O., Thomas G., and Gadner H. EWS/FLI-1 antagonists induce growth inhibition of Ewing tumor cells in vitro. Cell Growth Differ. 7 (1996) 429-437
17. Prieur A., Tirode F., Cohen P., and Delattre O. EWS/FLI-1 silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3. Mol. Cell. Biol. 24 (2004) 7275-7283
18. Tanaka K., Iwakuma T., Harimaya K., Sato H., and Iwamoto Y. EWS-Fli1 antisense oligodeoxynucleotide inhibits proliferation of human Ewing's sarcoma and primitive neuroectodermal tumor cells. J. Clin. Invest. 99 (1997) 239-247
19. Chansky H.A., Barahmand-Pour F., Mei Q., Kahn-Farooqi W., Zielinska-Kwiatkowska A., Blackburn M., Chansky K., Conrad III E.U., Bruckner J.D., Greenlee T.K., and Yang L. Targeting of EWS/FLI-1 by RNA interference attenuates the tumor phenotype of Ewing's sarcoma cells in vitro. J. Orthop. Res. 22 (2004) 910-917
20. Hu-Lieskovan S., Heidel J.D., Bartlett D.W., Davis M.E., and Triche T.J. Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma. Cancer Res. 65 (2005) 8984-8992
21. Lambert G., Bertrand J.R., Fattal E., Subra F., Pinto-Alphandary H., Malvy C., Auclair C., and Couvreur P. EWS fli-1 antisense nanocapsules inhibits ewing sarcoma-related tumor in mice. Biochem. Biophys. Res. Commun. 279 (2000) 401-406
22. Ouchida M., Ohno T., Fujimura Y., Rao V.N., and Reddy E.S. Loss of tumorigenicity of Ewing's sarcoma cells expressing antisense RNA to EWS-fusion transcripts. Oncogene 11 (1995) 1049-1054
23. Hu H.M., Zielinska-Kwiatkowska A., Munro K., Wilcox J., Wu D.Y., Yang L., and Chansky H.A. EWS/FLI1 suppresses retinoblastoma protein function and senescence in Ewing's sarcoma cells. J. Orthop. Res. 26 (2008) 886-893
24. Matsunobu T., Tanaka K., Nakamura T., Nakatani F., Sakimura R., Hanada M., Li X., Okada T., Oda Y., Tsuneyoshi M., and Iwamoto Y. The possible role of EWS-Fli1 in evasion of senescence in Ewing family tumors. Cancer Res. 66 (2006) 803-811
25. Bailly R.A., Bosselut R., Zucman J., Cormier F., Delattre O., Roussel M., Thomas G., and Ghysdael J. DNA-binding and transcriptional activation properties of the EWS-FLI-1 fusion protein resulting from the t(11;22) translocation in Ewing sarcoma. Mol. Cell Biol. 14 (1994) 3230-3241
26. Ladanyi M. EWS-FLI1 and Ewing's sarcoma: recent molecular data and new insights. Cancer Biol. Ther. 1 (2002) 330-336
27. May W.A., Lessnick S.L., Braun B.S., Klemsz M., Lewis B.C., Lunsford L.B., Hromas R., and Denny C.T. The Ewing's sarcoma EWS/FLI-1 fusion gene encodes a more potent transcriptional activator and is a more powerful transforming gene than FLI-1. Mol. Cell. Biol. 13 (1993) 7393-7398
28. Ohno T., Rao V.N., and Reddy E.S. EWS/Fli-1 chimeric protein is a transcriptional activator. Cancer Res. 53 (1993) 5859-5863
29. Siligan C., Ban J., Bachmaier R., Spahn L., Kreppel M., Schaefer K.L., Poremba C., Aryee D.N., and Kovar H. EWS-FLI1 target genes recovered from Ewing's sarcoma chromatin. Oncogene 24 (2005) 2512-2524
30. Jaishankar S., Zhang J., Roussel M.F., and Baker S.J. Transforming activity of EWS/FLI is not strictly dependent upon DNA-binding activity. Oncogene 18 (1999) 5592-5597
31. Chansky H.A., Hu M., Hickstein D.D., and Yang L. Oncogenic TLS/ERG and EWS/Fli-1 fusion proteins inhibit RNA splicing mediated by YB-1 protein. Cancer Res. 61 (2001) 3586-3590
32. Knoop L.L., and Baker S.J. EWS/FLI alters 5′-splice site selection. J. Biol. Chem. 276 (2001) 22317-22322
33. Yang L., Chansky H.A., and Hickstein D.D. EWS.Fli-1 fusion protein interacts with hyperphosphorylated RNA polymerase II and interferes with serine-arginine protein-mediated RNA splicing. J. Biol. Chem. 275 (2000) 37612-37618
34. Roberts P., Burchill S.A., Brownhill S., Cullinane C.J., Johnston C., Griffiths M.J., McMullan D.J., Bown N.P., Morris S.P., and Lewis I.J. Ploidy and karyotype complexity are powerful prognostic indicators in the Ewing's sarcoma family of tumors: a study by the United Kingdom Cancer Cytogenetics and the Children's Cancer and Leukaemia Group. Genes Chromosomes Cancer 47 (2008) 207-220
35. Zielenska M., Zhang Z.M., Ng K., Marrano P., Bayani J., Ramirez O.C., Sorensen P., Thorner P., Greenberg M., and Squire J.A. Acquisition of secondary structural chromosomal changes in pediatric ewing sarcoma is a probable prognostic factor for tumor response and clinical outcome. Cancer 91 (2001) 2156-2164
36. Betts D.R., Avoledo P., von der Weid N., Greiner J., and Niggli F.K. Cytogenetic characterization of Ewing tumors with high-ploidy. Cancer Genet. Cytogenet. 159 (2005) 160-163
37. Niggli F.K., Powell J.E., Parkes S.E., Ward K., Raafat F., Mann J.R., and Stevens M.C. DNA ploidy and proliferative activity (S-phase) in childhood soft-tissue sarcomas: their value as prognostic indicators. Br. J. Cancer 69 (1994) 1106-1110
38. Armengol G., Tarkkanen M., Virolainen M., Forus A., Valle J., Bohling T., Asko-Seljavaara S., Blomqvist C., Elomaa I., Karaharju E., Kivioja A.H., Siimes M.A., Tukiainen E., Caballin M.R., Myklebost O., and Knuutila S. Recurrent gains of 1q, 8 and 12 in the Ewing family of tumours by comparative genomic hybridization. Br. J. Cancer 75 (1997) 1403-1409
39. Hattinger C.M., Rumpler S., Strehl S., Ambros I.M., Zoubek A., Potschger U., Gadner H., and Ambros P.F. Prognostic impact of deletions at 1p36 and numerical aberrations in Ewing tumors. Genes Chromosomes Cancer 24 (1999) 243-254
40. Maurici D., Perez-Atayde A., Grier H.E., Baldini N., Serra M., and Fletcher J.A. Frequency and implications of chromosome 8 and 12 gains in Ewing sarcoma. Cancer Genet. Cytogenet. 100 (1998) 106-110
41. Tarkkanen M., Kiuru-Kuhlefelt S., Blomqvist C., Armengol G., Bohling T., Ekfors T., Virolainen M., Lindholm P., Monge O., Picci P., Knuutila S., and Elomaa I. Clinical correlations of genetic changes by comparative genomic hybridization in Ewing sarcoma and related tumors. Cancer Genet. Cytogenet. 114 (1999) 35-41
42. Brisset S., Schleiermacher G., Peter M., Mairal A., Oberlin O., Delattre O., and Aurias A. CGH analysis of secondary genetic changes in Ewing tumors: correlation with metastatic disease in a series of 43 cases. Cancer Genet. Cytogenet. 130 (2001) 57-61
43. Douglass E.C., Rowe S.T., Valentine M., Parham D., Meyer W.H., and Thompson E.I. A second nonrandom translocation, der(16)t(1;16)(q21;q13), in Ewing sarcoma and peripheral neuroectodermal tumor. Cytogenet. Cell Genet. 53 (1990) 87-90
44. Kovar H., Jug G., Aryee D.N., Zoubek A., Ambros P., Gruber B., Windhager R., and Gadner H. Among genes involved in the RB dependent cell cycle regulatory cascade, the p16 tumor suppressor gene is frequently lost in the Ewing family of tumors. Oncogene 15 (1997) 2225-2232
45. Kullendorff C.M., Mertens F., Donner M., Wiebe T., Akerman M., and Mandahl N. Cytogenetic aberrations in Ewing sarcoma: are secondary changes associated with clinical outcome?. Med. Pediatr. Oncol. 32 (1999) 79-83
46. Mugneret F., Lizard S., Aurias A., and Turc-Carel C. Chromosomes in Ewing's sarcoma. II. Nonrandom additional changes, trisomy 8 and der(16)t(1;16). Cancer Genet. Cytogenet. 32 (1988) 239-245
47. Huang H.Y., Illei P.B., Zhao Z., Mazumdar M., Huvos A.G., Healey J.H., Wexler L.H., Gorlick R., Meyers P., and Ladanyi M. Ewing sarcomas with p53 mutation or p16/p14ARF homozygous deletion: a highly lethal subset associated with poor chemoresponse. J. Clin. Oncol. 23 (2005) 548-558
48. Lopez-Guerrero J.A., Pellin A., Noguera R., Carda C., and Llombart-Bosch A. Molecular analysis of the 9p21 locus and p53 genes in Ewing family tumors. Lab. Invest. 81 (2001) 803-814
49. Maitra A., Roberts H., Weinberg A.G., and Geradts J. Aberrant expression of tumor suppressor proteins in the Ewing family of tumors. Arch. Pathol. Lab. Med. 125 (2001) 1207-1212
50. Wei G., Antonescu C.R., de Alava E., Leung D., Huvos A.G., Meyers P.A., Healey J.H., and Ladanyi M. Prognostic impact of INK4A deletion in Ewing sarcoma. Cancer 89 (2000) 793-799
51. Hattinger C.M., Potschger U., Tarkkanen M., Squire J., Zielenska M., Kiuru-Kuhlefelt S., Kager L., Thorner P., Knuutila S., Niggli F.K., Ambros P.F., Gadner H., and Betts D.R. Prognostic impact of chromosomal aberrations in Ewing tumours. Br. J. Cancer 86 (2002) 1763-1769
52. Ozaki T., Paulussen M., Poremba C., Brinkschmidt C., Rerin J., Ahrens S., Hoffmann C., Hillmann A., Wai D., Schaefer K.L., Boecker W., Juergens H., Winkelmann W., and Dockhorn-Dworniczak B. Genetic imbalances revealed by comparative genomic hybridization in Ewing tumors. Genes Chromosomes Cancer 32 (2001) 164-171
53. Brownhill S.C., Taylor C., and Burchill S.A. Chromosome 9p21 gene copy number and prognostic significance of p16 in ESFT. Br. J. Cancer 96 (2007) 1914-1923
54. Tsuchiya T., Sekine K., Hinohara S., Namiki T., Nobori T., and Kaneko Y. Analysis of the p16INK4, p14ARF, p15, TP53, and MDM2 genes and their prognostic implications in osteosarcoma and Ewing sarcoma. Cancer Genet. Cytogenet. 120 (2000) 91-98
55. de Alava E., Antonescu C.R., Panizo A., Leung D., Meyers P.A., Huvos A.G., Pardo-Mindan F.J., Healey J.H., and Ladanyi M. Prognostic impact of P53 status in Ewing sarcoma. Cancer 89 (2000) 783-792
56. Matsunobu T., Tanaka K., Matsumoto Y., Nakatani F., Sakimura R., Hanada M., Li X., Oda Y., Naruse I., Hoshino H., Tsuneyoshi M., Miura H., and Iwamoto Y. The prognostic and therapeutic relevance of p27kip1 in Ewing's family tumors. Clin. Cancer Res. 10 (2004) 1003-1012
57. Patino-Garcia A., and Sierrasesumaga L. Analysis of the p16INK4 and TP53 tumor suppressor genes in bone sarcoma pediatric patients. Cancer Genet. Cytogenet. 98 (1997) 50-55
58. Toguchida J., Yamaguchi T., Ritchie B., Beauchamp R.L., Dayton S.H., Herrera G.E., Yamamuro T., Kotoura Y., Sasaki M.S., Little J.B., et al. Mutation spectrum of the p53 gene in bone and soft tissue sarcomas. Cancer Res. 52 (1992) 6194-6199
59. Kovar H., Auinger A., Jug G., Aryee D., Zoubek A., Salzer-Kuntschik M., and Gadner H. Narrow spectrum of infrequent p53 mutations and absence of MDM2 amplification in Ewing tumours. Oncogene 8 (1993) 2683-2690
60. Abudu A., Mangham D.C., Reynolds G.M., Pynsent P.B., Tillman R.M., Carter S.R., and Grimer R.J. Overexpression of p53 protein in primary Ewing's sarcoma of bone: relationship to tumour stage, response and prognosis. Br. J. Cancer 79 (1999) 1185-1189
61. Amir G., Issakov J., Meller I., Sucher E., Peyser A., Cohen I.J., Yaniv I., Ben Arush M.W., Tavori U., Kollender Y., Ron N., and Peylan-Ramu N. Expression of p53 gene product and cell proliferation marker Ki-67 in Ewing's sarcoma: correlation with clinical outcome. Hum. Pathol. 33 (2002) 170-174
62. Baer C., Nees M., Breit S., Selle B., Kulozik A.E., Schaefer K.L., Braun Y., Wai D., and Poremba C. Profiling and functional annotation of mRNA gene expression in pediatric rhabdomyosarcoma and Ewing's sarcoma. Int. J. Cancer 110 (2004) 687-694
63. Bandres E., Malumbres R., Escalada A., Cubedo E., Gonzalez I., Honorato B., Zarate R., Garcia-Foncillas J., and de Alava E. Gene expression profile of ewing sarcoma cell lines differing in their EWS-FLI1 fusion type. J. Pediatr. Hematol. Oncol. 27 (2005) 537-542
64. Davicioni E., Wai D.H., and Anderson M.J. Diagnostic and prognostic sarcoma signatures. Mol. Diagn. Ther. 12 (2008) 359-374
65. Ferreira B.I., Alonso J., Carrillo J., Acquadro F., Largo C., Suela J., Teixeira M.R., Cerveira N., Molares A., Gomez-Lopez G., Pestana A., Sastre A., Garcia-Miguel P., and Cigudosa J.C. Array CGH and gene-expression profiling reveals distinct genomic instability patterns associated with DNA repair and cell-cycle checkpoint pathways in Ewing's sarcoma. Oncogene 27 (2008) 2084-2090
66. Ohali A., Avigad S., Zaizov R., Ophir R., Horn-Saban S., Cohen I.J., Meller I., Kollender Y., Issakov J., and Yaniv I. Prediction of high risk Ewing's sarcoma by gene expression profiling. Oncogene 23 (2004) 8997-9006
67. Schaefer K.L., Eisenacher M., Braun Y., Brachwitz K., Wai D.H., Dirksen U., Lanvers-Kaminsky C., Juergens H., Herrero D., Stegmaier S., Koscielniak E., Eggert A., Nathrath M., Gosheger G., Schneider D.T., Bury C., Diallo-Danebrock R., Ottaviano L., Gabbert H.E., and Poremba C. Microarray analysis of Ewing's sarcoma family of tumours reveals characteristic gene expression signatures associated with metastasis and resistance to chemotherapy. Eur. J. Cancer 44 (2008) 699-709
68. Staege M.S., Hutter C., Neumann I., Foja S., Hattenhorst U.E., Hansen G., Afar D., and Burdach S.E. DNA microarrays reveal relationship of Ewing family tumors to both endothelial and fetal neural crest-derived cells and define novel targets. Cancer Res. 64 (2004) 8213-8221
69. Tirode F., Laud-Duval K., Prieur A., Delorme B., Charbord P., and Delattre O. Mesenchymal stem cell features of Ewing tumors. Cancer Cell. 11 (2007) 421-429
70. Miyagawa Y., Okita H., Nakaijima H., Horiuchi Y., Sato B., Taguchi T., Toyoda M., Katagiri Y.U., Fujimoto J., Hata J., Umezawa A., and Kiyokawa N. Inducible expression of chimeric EWS/ETS proteins confers Ewing's family tumor-like phenotypes to human mesenchymal progenitor cells. Mol. Cell. Biol. 28 (2008) 2125-2137
71. Riggi N., Suva M.L., Suva D., Cironi L., Provero P., Tercier S., Joseph J.M., Stehle J.C., Baumer K., Kindler V., and Stamenkovic I. EWS-FLI-1 expression triggers a Ewing's sarcoma initiation program in primary human mesenchymal stem cells. Cancer Res. 68 (2008) 2176-2185
72. Cavazzana A.O., Miser J.S., Jefferson J., and Triche T.J. Experimental evidence for a neural origin of Ewing's sarcoma of bone. Am. J. Pathol. 127 (1987) 507-518
73. Noguera R., Triche T.J., Navarro S., Tsokos M., and Llombart-Bosch A. Dynamic model of differentiation in Ewing's sarcoma cells. Comparative analysis of morphologic, immunocytochemical, and oncogene expression parameters. Lab. Invest. 66 (1992) 143-151
74. O'Regan S., Diebler M.F., Meunier F.M., and Vyas S. A Ewing's sarcoma cell line showing some, but not all, of the traits of a cholinergic neuron. J. Neurochem. 64 (1995) 69-76
75. Thiele C.J. Pediatric peripheral neuroectodermal tumors, oncogenes, and differentiation. Cancer Invest. 8 (1990) 629-639
76. Coles E.G., Lawlor E.R., and Bronner-Fraser M. EWS-FLI1 causes neuroepithelial defects and abrogates emigration of neural crest stem cells. Stem Cells 26 (2008) 2237-2244
77. Codrington R., Pannell R., Forster A., Drynan L.F., Daser A., Lobato N., Metzler M., and Rabbitts T.H. The Ews-ERG fusion protein can initiate neoplasia from lineage-committed haematopoietic cells. PLoS Biol. 3 (2005) e242
78. Castillero-Trejo Y., Eliazer S., Xiang L., Richardson J.A., and Ilaria Jr. R.L. Expression of the EWS/FLI-1 oncogene in murine primary bone-derived cells Results in EWS/FLI-1-dependent, ewing sarcoma-like tumors. Cancer Res. 65 (2005) 8698-8705
79. Teitell M.A., Thompson A.D., Sorensen P.H., Shimada H., Triche T.J., and Denny C.T. EWS/ETS fusion genes induce epithelial and neuroectodermal differentiation in NIH 3T3 fibroblasts. Lab. Invest. 79 (1999) 1535-1543
80. Takahashi A., Higashino F., Aoyagi M., Yoshida K., Itoh M., Kyo S., Ohno T., Taira T., Ariga H., Nakajima K., Hatta M., Kobayashi M., Sano H., Kohgo T., and Shindoh M. EWS/ETS fusions activate telomerase in Ewing's tumors. Cancer Res. 63 (2003) 8338-8344
81. Ohali A., Avigad S., Cohen I.J., Meller I., Kollender Y., Issakov J., Gelernter I., Goshen Y., Yaniv I., and Zaizov R. Association between telomerase activity and outcome in patients with nonmetastatic Ewing family of tumors. J. Clin. Oncol. 21 (2003) 3836-3843
82. Sotillo-Pineiro E., Sierrasesumaga L., and Patinno-Garcia A. Telomerase activity and telomere length in primary and metastatic tumors from pediatric bone cancer patients. Pediatr. Res. 55 (2004) 231-235
83. Ulaner G.A., Hoffman A.R., Otero J., Huang H.Y., Zhao Z., Mazumdar M., Gorlick R., Meyers P., Healey J.H., and Ladanyi M. Divergent patterns of telomere maintenance mechanisms among human sarcomas: sharply contrasting prevalence of the alternative lengthening of telomeres mechanism in Ewing's sarcomas and osteosarcomas. Genes Chromosomes Cancer 41 (2004) 155-162
84. Kleideiter E., Schwab M., Friedrich U., Koscielniak E., Schafer B.W., and Klotz U. Telomerase activity in cell lines of pediatric soft tissue sarcomas. Pediatr. Res. 54 (2003) 718-723
85. Lanvers-Kaminsky C., Winter B., Koling S., Frodermann B., Braun Y., Schaefer K.L., Diallo R., Koenemann S., Wai D., Willich N., Poremba C., and Schuck A. Doxorubicin modulates telomerase activity in Ewing's sarcoma in vitro and in vivo. Oncol. Rep. 14 (2005) 751-758
86. Fuchs B., Inwards C., Scully S.P., and Janknecht R. hTERT Is highly expressed in Ewing's sarcoma and activated by EWS-ETS oncoproteins. Clin. Orthop. Relat. Res. (2004) 64-68
87. Ghaffari S.H., Shayan-Asl N., Jamialahmadi A.H., Alimoghaddam K., and Ghavamzadeh A. Telomerase activity and telomere length in patients with acute promyelocytic leukemia: indicative of proliferative activity, disease progression, and overall survival. Ann. Oncol. 19 (2008) 1927-1934
88. Kolquist K.A., Ellisen L.W., Counter C.M., Meyerson M., Tan L.K., Weinberg R.A., Haber D.A., and Gerald W.L. Expression of TERT in early premalignant lesions and a subset of cells in normal tissues. Nat. Genet. 19 (1998) 182-186
89. Uziel O., Fenig E., Nordenberg J., Beery E., Reshef H., Sandbank J., Birenbaum M., Bakhanashvili M., Yerushalmi R., Luria D., and Lahav M. Imatinib mesylate (Gleevec) downregulates telomerase activity and inhibits proliferation in telomerase-expressing cell lines. Br. J. Cancer 92 (2005) 1881-1891
90. Wang J., Xie L.Y., Allan S., Beach D., and Hannon G.J. Myc activates telomerase. Genes Dev. 12 (1998) 1769-1774
91. Wu K.J., Grandori C., Amacker M., Simon-Vermot N., Polack A., Lingner J., and Dalla-Favera R. Direct activation of TERT transcription by c-MYC. Nat. Genet. 21 (1999) 220-224
92. Dauphinot L., De Oliveira C., Melot T., Sevenet N., Thomas V., Weissman B.E., and Delattre O. Analysis of the expression of cell cycle regulators in Ewing cell lines: EWS-FLI-1 modulates p57KIP2and c-Myc expression. Oncogene 20 (2001) 3258-3265
93. Cao Y., Bryan T.M., and Reddel R.R. Increased copy number of the TERT and TERC telomerase subunit genes in cancer cells. Cancer Sci. 99 (2008) 1092-1099
94. Dunst J., Ahrens S., Paulussen M., Burdach S., and Jurgens H. Prognostic impact of tumor perfusion in MR-imaging studies in Ewing tumors. Strahlenther. Onkol. 177 (2001) 153-159
95. Nishi H., Nakada T., Kyo S., Inoue M., Shay J.W., and Isaka K. Hypoxia-inducible factor 1 mediates upregulation of telomerase (hTERT). Mol. Cell. Biol. 24 (2004) 6076-6083
96. Yatabe N., Kyo S., Maida Y., Nishi H., Nakamura M., Kanaya T., Tanaka M., Isaka K., Ogawa S., and Inoue M. HIF-1-mediated activation of telomerase in cervical cancer cells. Oncogene 23 (2004) 3708-3715
97. Anderson C.J., Hoare S.F., Ashcroft M., Bilsland A.E., and Keith W.N. Hypoxic regulation of telomerase gene expression by transcriptional and post-transcriptional mechanisms. Oncogene 25 (2006) 61-69
98. Lou F., Chen X., Jalink M., Zhu Q., Ge N., Zhao S., Fang X., Fan Y., Bjorkholm M., Liu Z., and Xu D. The opposing effect of hypoxia-inducible factor-2alpha on expression of telomerase reverse transcriptase. Mol. Cancer Res. 5 (2007) 793-800
99. Bardos J.I., and Ashcroft M. Negative and positive regulation of HIF-1: a complex network. Biochim. Biophys. Acta 1755 (2005) 107-120
100. Colgin L.M., Wilkinson C., Englezou A., Kilian A., Robinson M.O., and Reddel R.R. The hTERTalpha splice variant is a dominant negative inhibitor of telomerase activity. Neoplasia 2 (2000) 426-432
101. Kilian A., Bowtell D.D., Abud H.E., Hime G.R., Venter D.J., Keese P.K., Duncan E.L., Reddel R.R., and Jefferson R.A. Isolation of a candidate human telomerase catalytic subunit gene, which reveals complex splicing patterns in different cell types. Hum. Mol. Genet. 6 (1997) 2011-2019
102. Saeboe-Larssen S., Fossberg E., and Gaudernack G. Characterization of novel alternative splicing sites in human telomerase reverse transcriptase (hTERT): analysis of expression and mutual correlation in mRNA isoforms from normal and tumour tissues. BMC Mol. Biol. 7 (2006) 26
103. Ulaner G.A., Hu J.F., Vu T.H., Oruganti H., Giudice L.C., and Hoffman A.R., Regulation of telomerase by alternate splicing of human telomerase reverse transcriptase (hTERT) in normal and neoplastic ovary, endometrium and myometrium. Int. J. Cancer 85 (2000) 330-335
104. Yi X., Shay J.W., and Wright W.E. Quantitation of telomerase components and hTERT mRNA splicing patterns in immortal human cells. Nucleic Acids Res. 29 (2001) 4818-4825
105. Avigad S., Naumov I., Ohali A., Jeison M., Berco G.H., Mardoukh J., Stark B., Ash S., Cohen I.J., Meller I., Kollender Y., Issakov J., and Yaniv I. Short telomeres: a novel potential predictor of relapse in ewing sarcoma. Clin. Cancer Res. 13 (2007) 5777-5783
106. Montgomery E., Argani P., Hicks J.L., DeMarzo A.M., and Meeker A.K. Telomere lengths of translocation-associated and nontranslocation-associated sarcomas differ dramatically. Am. J. Pathol. 164 (2004) 1523-1529
107. Meeker A.K., Hicks J.L., Iacobuzio-Donahue C.A., Montgomery E.A., Westra W.H., Chan T.Y., Ronnett B.M., and De Marzo A.M. Telomere length abnormalities occur early in the initiation of epithelial carcinogenesis. Clin. Cancer Res. 10 (2004) 3317-3326
108. Wu X., Amos C.I., Zhu Y., Zhao H., Grossman B.H., Shay J.W., Luo S., Hong W.K., and Spitz M.R. Telomere dysfunction: a potential cancer predisposition factor. J. Natl. Cancer Inst. 95 (2003) 1211-1218
109. Hanson H., Mathew C.G., Docherty Z., and Mackie Ogilvie C. Telomere shortening in Fanconi anaemia demonstrated by a direct FISH approach. Cytogenet. Cell Genet. 93 (2001) 203-206
110. Cong Y., and Shay J.W. Actions of human telomerase beyond telomeres. Cell Res. 18 (2008) 725-732
111. Harley C.B. Telomerase and cancer therapeutics. Nat. Rev. Cancer 8 (2008) 167-179
112. Kelland L. Targeting the limitless replicative potential of cancer: the telomerase/telomere pathway. Clin. Cancer Res. 13 (2007) 4960-4963
113. Shay J.W., and Keith W.N. Targeting telomerase for cancer therapeutics. Br. J. Cancer 98 (2008) 677-683
114. Bollmann F.M. The many faces of telomerase: emerging extratelomeric effects. Bioessays 30 (2008) 728-732
115. Ohyashiki K., Ohyashiki J.H., Nishimaki J., Toyama K., Ebihara Y., Kato H., Wright W.E., and Shay J.W. Cytological detection of telomerase activity using an in situ telomeric repeat amplification protocol assay. Cancer Res. 57 (1997) 2100-2103
116. Uehara H., Nakaizumi A., Iishi H., Takenaka A., Eguchi H., Ohigashi H., and Ishikawa O. In situ telomerase activity in pancreatic juice may discriminate pancreatic cancer from other pancreatic diseases. Pancreas 36 (2008) 236-240
117. Cheng Y.W., Wu T.C., Chen C.Y., Chou M.C., Ko J.L., and Lee H. Human telomerase reverse transcriptase activated by E6 oncoprotein is required for human papillomavirus-16/18-infected lung tumorigenesis. Clin. Cancer Res. 14 (2008) 7173-7179
118. Chou S.J., Chen C.M., Harn H.J., Chen C.J., and Liu Y.C. In situ detection of hTERT mRNA relates to Ki-67 labeling index in papillary thyroid carcinoma. J. Surg. Res. 99 (2001) 75-83
119. Kumaki F., Kawai T., Hiroi S., Shinomiya N., Ozeki Y., Ferrans V.J., and Torikata C. Telomerase activity and expression of human telomerase RNA component and human telomerase reverse transcriptase in lung carcinomas. Hum. Pathol. 32 (2001) 188-195
120. Shammas M.A., Qazi A., Batchu R.B., Bertheau R.C., Wong J.Y., Rao M.Y., Prasad M., Chanda D., Ponnazhagan S., Anderson K.C., Steffes C.P., Munshi N.C., De Vivo I., Beer D.G., Gryaznov S., Weaver D.W., and Goyal R.K. Telomere maintenance in laser capture microdissection-purified Barrett's adenocarcinoma cells and effect of telomerase inhibition in vivo. Clin. Cancer Res. 14 (2008) 4971-4980
121. Wu Y.Y., Hruszkewycz A.M., Delgado R.M., Yang A., Vortmeyer A.O., Moon Y.W., Weil R.J., Zhuang Z., and Remaley A.T. Limitations on the quantitative determination of telomerase activity by the electrophoretic and ELISA based TRAP assays. Clin. Chim. Acta 293 (2000) 199-212
122. Baerlocher G.M., Mak J., Tien T., and Lansdorp P.M. Telomere length measurement by fluorescence in situ hybridization and flow cytometry: tips and pitfalls. Cytometry 47 (2002) 89-99
123. Hultdin M., Gronlund E., Norrback K., Eriksson-Lindstrom E., Just T., and Roos G. Telomere analysis by fluorescence in situ hybridization and flow cytometry. Nucleic Acids Res. 26 (1998) 3651-3656
124. Rufer N., Brummendorf T.H., Kolvraa S., Bischoff C., Christensen K., Wadsworth L., Schulzer M., and Lansdorp P.M. Telomere fluorescence measurements in granulocytes and T lymphocyte subsets point to a high turnover of hematopoietic stem cells and memory T cells in early childhood. J. Exp. Med. 190 (1999) 157-167
125. Rufer N., Dragowska W., Thornbury G., Roosnek E., and Lansdorp P.M. Telomere length dynamics in human lymphocyte subpopulations measured by flow cytometry. Nat. Biotechnol. 16 (1998) 743-747
126. Cawthon R.M. Telomere measurement by quantitative PCR. Nucleic Acids Res. 30 (2002) e47
127. Svenson U., Nordfjall K., Stegmayr B., Manjer J., Nilsson P., Tavelin B., Henriksson R., Lenner P., and Roos G. Breast cancer survival is associated with telomere length in peripheral blood cells. Cancer Res. 68 (2008) 3618-3623
128. Zhang Y., Shen J., Ming W., Lee Y.P., and Santella R.M. Telomere length in hepatocellular carcinoma and paired adjacent non-tumor tissues by quantitative PCR. Cancer Invest. 25 (2007) 668-677
129. Baird D.M., Rowson J., Wynford-Thomas D., and Kipling D. Extensive allelic variation and ultrashort telomeres in senescent human cells. Nat. Genet. 33 (2003) 203-207
130. Xu L., and Blackburn E.H. Human cancer cells harbor T-stumps, a distinct class of extremely short telomeres. Mol. Cell 28 (2007) 315-327
131. Britt-Compton B., Rowson J., Locke M., Mackenzie I., Kipling D., and Baird D.M. Structural stability and chromosome-specific telomere length is governed by cis-acting determinants in humans. Hum. Mol. Genet. 15 (2006) 725-733
132. Kim N.W., Piatyszek M.A., Prowse K.R., Harley C.B., West M.D., Ho P.L., Coviello G.M., Wright W.E., Weinrich S.L., and Shay J.W. Specific association of human telomerase activity with immortal cells and cancer. Science 266 (1994) 2011-2015
133. Piatyszek M.A., Kim N.W., Weinrich S.L., Hiyama K., Hiyama E., Wright W.E., and Shay J.W. Detection of telomerase activity in human cells and tumors by a telomeric repeat amplification protocol (TRAP). Methods Cell Sci. 17 (1995) 1-15
134. Aldous W.K., and Grabill N.R. A fluorescent method for detection of telomerase activity. Diagn. Mol. Pathol. 6 (1997) 102-110
135. Fajkus J., Fulneckova J., Hulanova M., Berkova K., Riha K., and Matyasek R. Plant cells express telomerase activity upon transfer to callus culture, without extensively changing telomere lengths. Mol. Gen. Genet. 260 (1998) 470-474
136. Riha K., Fajkus J., Siroky J., and Vyskot B. Developmental control of telomere lengths and telomerase activity in plants. Plant Cell 10 (1998) 1691-1698
137. Wright W.E., Shay J.W., and Piatyszek M.A. Modifications of a telomeric repeat amplification protocol (TRAP) result in increased reliability, linearity and sensitivity. Nucleic Acids Res. 23 (1995) 3794-3795
138. Hiyama K., Hirai Y., Kyoizumi S., Akiyama M., Hiyama E., Piatyszek M.A., Shay J.W., Ishioka S., and Yamakido M. Activation of telomerase in human lymphocytes and hematopoietic progenitor cells. J. Immunol. 155 (1995) 3711-3715
139. Hiyama K., Hiyama E., Ishioka S., Yamakido M., Inai K., Gazdar A.F., Piatyszek M.A., and Shay J.W. Telomerase activity in small-cell and non-small-cell lung cancers. J. Natl. Cancer Inst. 87 (1995) 895-902
140. Hiyama E., Gollahon L., Kataoka T., Kuroi K., Yokoyama T., Gazdar A.F., Hiyama K., Piatyszek M.A., and Shay J.W. Telomerase activity in human breast tumors. J. Natl. Cancer Inst. 88 (1996) 116-122
141. Matthews P., Jones C.J., Skinner J., Haughton M., de Micco C., and Wynford-Thomas D. Telomerase activity and telomere length in thyroid neoplasia: biological and clinical implications. J. Pathol. 194 (2001) 183-193
142. Jakupciak J.P., Barker P.E., Wang W., Srivastava S., and Atha D.H. Preparation and characterization of candidate reference materials for telomerase assays. Clin. Chem. 51 (2005) 1443-1450
143. Buttitta F., Pellegrini C., Marchetti A., Gadducci A., Cosio S., Felicioni L., Barassi F., Salvatore S., Martella C., Coggi G., and Bosari S. Human telomerase reverse transcriptase mRNA expression assessed by real-time reverse transcription polymerase chain reaction predicts chemosensitivity in patients with ovarian carcinoma. J. Clin. Oncol. 21 (2003) 1320-1325
144. Sun P.M., Wei L.H., Luo M.Y., Liu G., Wang J.L., Mustea A., Konsgen D., Lichtenegger W., and Sehouli J. The telomerase activity and expression of hTERT gene can serve as indicators in the anti-cancer treatment of human ovarian cancer. Eur. J. Obstet. Gynecol. Reprod. Biol. 130 (2007) 249-257
145. Cong Y.S., Wright W.E., and Shay J.W. Human telomerase and its regulation. Microbiol. Mol. Biol. Rev. 66 (2002) 407-425 table of contents
146. Janknecht R. On the road to immortality: hTERT upregulation in cancer cells. FEBS Lett. 564 (2004) 9-13
147. Ulaner G.A., Hu J.F., Vu T.H., Giudice L.C., and Hoffman A.R. Telomerase activity in human development is regulated by human telomerase reverse transcriptase (hTERT) transcription and by alternate splicing of hTERT transcripts. Cancer Res. 58 (1998) 4168-4172
148. Avilion A.A., Piatyszek M.A., Gupta J., Shay J.W., Bacchetti S., and Greider C.W. Human telomerase RNA and telomerase activity in immortal cell lines and tumor tissues. Cancer Res. 56 (1996) 645-650
149. Blasco M.A., Lee H.W., Hande M.P., Samper E., Lansdorp P.M., DePinho R.A., and Greider C.W. Telomere shortening and tumor formation by mouse cells lacking telomerase RNA. Cell 91 (1997) 25-34
150. Feng J., Funk W.D., Wang S.S., Weinrich S.L., Avilion A.A., Chiu C.P., Adams R.R., Chang E., Allsopp R.C., Yu J., et al. The RNA component of human telomerase. Science 269 (1995) 1236-1241
151. Soder A.I., Going J.J., Kaye S.B., and Keith W.N. Tumour specific regulation of telomerase RNA gene expression visualized by in situ hybridization. Oncogene 16 (1998) 979-983
152. Poremba C., Scheel C., Hero B., Christiansen H., Schaefer K.L., Nakayama J., Berthold F., Juergens H., Boecker W., and Dockhorn-Dworniczak B. Telomerase activity and telomerase subunits gene expression patterns in neuroblastoma: a molecular and immunohistochemical study establishing prognostic tools for fresh-frozen and paraffin-embedded tissues. J. Clin. Oncol. 18 (2000) 2582-2592
153. Cairney C.J., Hoare S.F., Daidone M.G., Zaffaroni N., and Keith W.N. High level of telomerase RNA gene expression is associated with chromatin modification, the ALT phenotype and poor prognosis in liposarcoma. Br. J. Cancer 98 (2008) 1467-1474
154. Jakupciak J.P., Wang W., Barker P.E., Srivastava S., and Atha D.H. Analytical validation of telomerase activity for cancer early detection: TRAP/PCR-CE and hTERT mRNA quantification assay for high-throughput screening of tumor cells. J. Mol. Diagn. 6 (2004) 157-165
155. Jakupciak J.P. Real-time telomerase activity measurements for detection of cancer. Expert Rev. Mol. Diagn. 5 (2005) 745-753
156. Amiel A., Ohali A., Fejgin M., Sardos-Albertini F., Bouaron N., Cohen I.J., Yaniv I., Zaizov R., and Avigad S. Molecular cytogenetic parameters in Ewing sarcoma. Cancer Genet. Cytogenet. 140 (2003) 107-112
157. Sangiorgi L., Gobbi G.A., Lucarelli E., Sartorio S.M., Mordenti M., Ghedini I., Maini V., Scrimieri F., Reggiani M., Bertoja A.Z., Benassi M.S., and Picci P. Presence of telomerase activity in different musculoskeletal tumor histotypes and correlation with aggressiveness. Int. J. Cancer 95 (2001) 156-161
158. Ohali A., Avigad S., Ash S., Goshen Y., Luria D., Feinmesser M., Zaizov R., and Yaniv I. Telomere length is a prognostic factor in neuroblastoma. Cancer 107 (2006) 1391-1399
159. Hiyama E., Hiyama K., Yokoyama T., Matsuura Y., Piatyszek M.A., and Shay J.W. Correlating telomerase activity levels with human neuroblastoma outcomes. Nat. Med. 1 (1995) 249-255
160. Poremba C., Willenbring H., Hero B., Christiansen H., Schafer K.L., Brinkschmidt C., Jurgens H., Bocker W., and Dockhorn-Dworniczak B. Telomerase activity distinguishes between neuroblastomas with good and poor prognosis. Ann. Oncol. 10 (1999) 715-721
161. Krams M., Hero B., Berthold F., Parwaresch R., Harms D., and Rudolph P. Full-length telomerase reverse transcriptase messenger RNA is an independent prognostic factor in neuroblastoma. Am. J. Pathol. 162 (2003) 1019-1026
162. Choi L.M., Kim N.W., Zuo J.J., Gerbing R., Stram D., Lukens J.N., Matthay K.K., Seeger R.C., and Reynolds C.P. Telomerase activity by TRAP assay and telomerase RNA (hTR) expression are predictive of outcome in neuroblastoma. Med. Pediatr. Oncol. 35 (2000) 647-650
163. Streutker C.J., Thorner P., Fabricius N., Weitzman S., and Zielenska M. Telomerase activity as a prognostic factor in neuroblastomas. Pediatr. Dev. Pathol. 4 (2001) 62-67
164. Stewenius Y., Jin Y., Ora I., de Kraker J., Bras J., Frigyesi A., Alumets J., Sandstedt B., Meeker A.K., and Gisselsson D. Defective chromosome segregation and telomere dysfunction in aggressive Wilms' tumors. Clin. Cancer Res. 13 (2007) 6593-6602
165. Dome J.S., Bockhold C.A., Li S.M., Baker S.D., Green D.M., Perlman E.J., Hill D.A., and Breslow N.E. High telomerase RNA expression level is an adverse prognostic factor for favorable-histology Wilms' tumor. J. Clin. Oncol. 23 (2005) 9138-9145
166. Dome J.S., Chung S., Bergemann T., Umbricht C.B., Saji M., Carey L.A., Grundy P.E., Perlman E.J., Breslow N.E., and Sukumar S. High telomerase reverse transcriptase (hTERT) messenger RNA level correlates with tumor recurrence in patients with favorable histology Wilms' tumor. Cancer Res. 59 (1999) 4301-4307
167. Hiyama E., Yamaoka H., Matsunaga T., Hayashi Y., Ando H., Suita S., Horie H., Kaneko M., Sasaki F., Hashizume K., Nakagawara A., Ohnuma N., and Yokoyama T. High expression of telomerase is an independent prognostic indicator of poor outcome in hepatoblastoma. Br. J. Cancer 91 (2004) 972-979
168. Ulaner G.A., Huang H.Y., Otero J., Zhao Z., Ben-Porat L., Satagopan J.M., Gorlick R., Meyers P., Healey J.H., Huvos A.G., Hoffman A.R., and Ladanyi M. Absence of a telomere maintenance mechanism as a favorable prognostic factor in patients with osteosarcoma. Cancer Res. 63 (2003) 1759-1763
169. Yan P., Coindre J.M., Benhattar J., Bosman F.T., and Guillou L. Telomerase activity and human telomerase reverse transcriptase mRNA expression in soft tissue tumors: correlation with grade, histology, and proliferative activity. Cancer Res. 59 (1999) 3166-3170
170. Wurl P., Kappler M., Meye A., Bartel F., Kohler T., Lautenschlager C., Bache M., Schmidt H., and Taubert H. Co-expression of survivin and TERT and risk of tumour-related death in patients with soft-tissue sarcoma. Lancet 359 (2002) 943-945
171. Ohali A., Avigad S., Naumov I., Goshen Y., Ash S., and Yaniv I. Different telomere maintenance mechanisms in alveolar and embryonal rhabdomyosarcoma. Genes Chromosomes Cancer 47 (2008) 965-970
172. Schneider-Stock R., Boltze C., Jager V., Epplen J., Landt O., Peters B., Rys J., and Roessner A. Elevated telomerase activity, c-MYC-, and hTERT mRNA expression: association with tumour progression in malignant lipomatous tumours. J. Pathol. 199 (2003) 517-525
173. Schneider-Stock R., Jaeger V., Rys J., Epplen J.T., and Roessner A. High telomerase activity and high HTRT mRNA expression differentiate pure myxoid and myxoid/round-cell liposarcomas. Int. J. Cancer 89 (2000) 63-68
174. Rudolph P., Schubert C., Tamm S., Heidorn K., Hauschild A., Michalska I., Majewski S., Krupp G., Jablonska S., and Parwaresch R. Telomerase activity in melanocytic lesions: a potential marker of tumor biology. Am. J. Pathol. 156 (2000) 1425-1432
175. Carvalho L., Lipay M., Belfort F., Santos I., Andrade J., Haddad A., Brunstein F., and Ferreira L. Telomerase activity in prognostic histopathologic features of melanoma. J. Plast. Reconstr. Aesthet. Surg. 59 (2006) 961-968
176. De Kok J.B., Schalken J.A., Aalders T.W., Ruers T.J., Willems H.L., and Swinkels D.W. Quantitative measurement of telomerase reverse transcriptase (hTERT) mRNA in urothelial cell carcinomas. Int. J. Cancer 87 (2000) 217-220
177. Takihana Y., Tsuchida T., Fukasawa M., Araki I., Tanabe N., and Takeda M. Real-time quantitative analysis for human telomerase reverse transcriptase mRNA and human telomerase RNA component mRNA expressions as markers for clinicopathologic parameters in urinary bladder cancer. Int. J. Urol. 13 (2006) 401-408
178. Sanchini M.A., Gunelli R., Nanni O., Bravaccini S., Fabbri C., Sermasi A., Bercovich E., Ravaioli A., Amadori D., and Calistri D. Relevance of urine telomerase in the diagnosis of bladder cancer. JAMA 294 (2005) 2052-2056
179. Bautista C.V., Felis C.P., Espinet J.M., Garcia J.B., and Salas J.V. Telomerase activity is a prognostic factor for recurrence and survival in rectal cancer. Dis. Colon. Rectum. 50 (2007) 611-620
180. Tatsumoto N., Hiyama E., Murakami Y., Imamura Y., Shay J.W., Matsuura Y., and Yokoyama T. High telomerase activity is an independent prognostic indicator of poor outcome in colorectal cancer. Clin. Cancer Res. 6 (2000) 2696-2701
181. Smith D.L., Soria J.C., Morat L., Yang Q., Sabatier L., Liu D.D., Nemr R.A., Rashid A., and Vauthey J.N. Human telomerase reverse transcriptase (hTERT) and Ki-67 are better predictors of survival than established clinical indicators in patients undergoing curative hepatic resection for colorectal metastases. Ann. Surg. Oncol. 11 (2004) 45-51
182. Usselmann B., Newbold M., Morris A.G., and Nwokolo C.U. Telomerase activity and patient survival after surgery for gastric and oesophageal cancer. Eur. J. Gastroenterol. Hepatol. 13 (2001) 903-908
183. Hiyama E., Yokoyama T., Tatsumoto N., Hiyama K., Imamura Y., Murakami Y., Kodama T., Piatyszek M.A., Shay J.W., and Matsuura Y. Telomerase activity in gastric cancer. Cancer Res. 55 (1995) 3258-3262
184. Kakeji Y., Maehara Y., Koga T., Shibahara K., Kabashima A., Tokunaga E., and Sugimachi K. Gastric cancer with high telomerase activity shows rapid development and invasiveness. Oncol. Rep. 8 (2001) 107-110
185. Carey L.A., Kim N.W., Goodman S., Marks J., Henderson G., Umbricht C.B., Dome J.S., Dooley W., Amshey S.R., and Sukumar S. Telomerase activity and prognosis in primary breast cancers. J. Clin. Oncol. 17 (1999) 3075-3081
186. Mokbel K., Parris C.N., Radbourne R., Ghilchik M., and Newbold R.F. Telomerase activity and prognosis in breast cancer. Eur. J. Surg. Oncol. 25 (1999) 269-272
187. Clark G.M., Osborne C.K., Levitt D., Wu F., and Kim N.W. Telomerase activity and survival of patients with node-positive breast cancer. J. Natl. Cancer Inst. 89 (1997) 1874-1881
188. Kimura M., Koida T., and Yanagita Y. A study on telomerase activity and prognosis in breast cancer. Med. Oncol. 20 (2003) 117-126
189. Bieche I., Nogues C., Paradis V., Olivi M., Bedossa P., Lidereau R., and Vidaud M. Quantitation of hTERT gene expression in sporadic breast tumors with a real-time reverse transcription-polymerase chain reaction assay. Clin. Cancer Res. 6 (2000) 452-459
190. Poremba C., Heine B., Diallo R., Heinecke A., Wai D., Schaefer K.L., Braun Y., Schuck A., Lanvers C., Bankfalvi A., Kneif S., Torhorst J., Zuber M., Kochli O.R., Mross F., Dieterich H., Sauter G., Stein H., Fogt F., and Boecker W. Telomerase as a prognostic marker in breast cancer: high-throughput tissue microarray analysis of hTERT and hTR. J. Pathol. 198 (2002) 181-189
191. Gonzalez-Quevedo R., Iniesta P., Moran A., de Juan C., Sanchez-Pernaute A., Fernandez C., Torres A., Diaz-Rubio E., Balibrea J.L., and Benito M. Cooperative role of telomerase activity and p16 expression in the prognosis of non-small-cell lung cancer. J. Clin. Oncol. 20 (2002) 254-262
192. Taga S., Osaki T., Ohgami A., Imoto H., and Yasumoto K. Prognostic impact of telomerase activity in non-small cell lung cancers. Ann. Surg. 230 (1999) 715-720
193. Marchetti A., Pellegrini C., Buttitta F., Falleni M., Romagnoli S., Felicioni L., Barassi F., Salvatore S., Chella A., Angeletti C.A., Roncalli M., Coggi G., and Bosari S. Prediction of survival in stage I lung carcinoma patients by telomerase function evaluation. Lab. Invest. 82 (2002) 729-736
194. Frias C., Garcia-Aranda C., De Juan C., Moran A., Ortega P., Gomez A., Hernando F., Lopez-Asenjo J.A., Torres A.J., Benito M., and Iniesta P. Telomere shortening is associated with poor prognosis and telomerase activity correlates with DNA repair impairment in non-small cell lung cancer. Lung Cancer 60 (2008) 416-425
195. Chen Y.J., Hakin-Smith V., Teo M., Xinarianos G.E., Jellinek D.A., Carroll T., McDowell D., MacFarlane M.R., Boet R., Baguley B.C., Braithwaite A.W., Reddel R.R., and Royds J.A. Association of mutant TP53 with alternative lengthening of telomeres and favorable prognosis in glioma. Cancer Res. 66 (2006) 6473-6476
196. Hakin-Smith V., Jellinek D.A., Levy D., Carroll T., Teo M., Timperley W.R., McKay M.J., Reddel R.R., and Royds J.A. Alternative lengthening of telomeres and survival in patients with glioblastoma multiforme. Lancet 361 (2003) 836-838
197. Huang F., Kanno H., Yamamoto I., Lin Y., and Kubota Y. Correlation of clinical features and telomerase activity in human gliomas. J. Neurooncol. 43 (1999) 137-142
198. Falchetti M.L., Pallini R., D'Ambrosio E., Pierconti F., Martini M., Cimino-Reale G., Verna R., Maira G., and Larocca L.M. In situ detection of telomerase catalytic subunit mRNA in glioblastoma multiforme. Int. J. Cancer 88 (2000) 895-901
199. Carpentier C., Lejeune J., Gros F., Everhard S., Marie Y., Kaloshi G., Laigle-Donadey F., Hoang-Xuan K., Delattre J.Y., and Sanson M. Association of telomerase gene hTERT polymorphism and malignant gliomas. J. Neurooncol. 84 (2007) 249-253
200. Wang L., Wei Q., Wang L.E., Aldape K.D., Cao Y., Okcu M.F., Hess K.R., El-Zein R., Gilbert M.R., Woo S.Y., Prabhu S.S., Fuller G.N., and Bondy M.L. Survival prediction in patients with glioblastoma multiforme by human telomerase genetic variation. J. Clin. Oncol. 24 (2006) 1627-1632
201. Fan X., Wang Y., Kratz J., Brat D.J., Robitaille Y., Moghrabi A., Perlman E.J., Dang C.V., Burger P.C., and Eberhart C.G. hTERT gene amplification and increased mRNA expression in central nervous system embryonal tumors. Am. J. Pathol. 162 (2003) 1763-1769
202. Drummond M., Lennard A., Brummendorf T., and Holyoake T. Telomere shortening correlates with prognostic score at diagnosis and proceeds rapidly during progression of chronic myeloid leukemia. Leuk. Lymphoma 45 (2004) 1775-1781
203. Boultwood J., Peniket A., Watkins F., Shepherd P., McGale P., Richards S., Fidler C., Littlewood T.J., and Wainscoat J.S. Telomere length shortening in chronic myelogenous leukemia is associated with reduced time to accelerated phase. Blood 96 (2000) 358-361
204. Ohyashiki K., Ohyashiki J.H., Iwama H., Hayashi S., Shay J.W., and Toyama K. Telomerase activity and cytogenetic changes in chronic myeloid leukemia with disease progression. Leukemia 11 (1997) 190-194
205. Verstovsek S., Kantarjian H., Manshouri T., Cortes J., Faderl S., Giles F.J., Keating M., and Albitar M. Increased telomerase activity is associated with shorter survival in patients with chronic phase chronic myeloid leukemia. Cancer 97 (2003) 1248-1252
206. Ohyashiki J.H., Ohyashiki K., Iwama H., Hayashi S., Toyama K., and Shay J.W. Clinical implications of telomerase activity levels in acute leukemia. Clin. Cancer Res. 3 (1997) 619-625
207. Verstovsek S., Manshouri T., Smith F.O., Giles F.J., Cortes J., Estey E., Kantarjian H., Keating M., Jeha S., and Albitar M. Telomerase activity is prognostic in pediatric patients with acute myeloid leukemia: comparison with adult acute myeloid leukemia. Cancer 97 (2003) 2212-2217
208. Cogulu O., Kosova B., Gunduz C., Karaca E., Aksoylar S., Erbay A., Karapinar D., Vergin C., Vural F., Tombuloglu M., Cetingul N., and Ozkinay F. The evaluation of hTERT mRNA expression in acute leukemia children and 2 years follow-up of 40 cases. Int. J. Hematol. 87 (2008) 276-283
209. Xu D., Gruber A., Peterson C., and Pisa P. Telomerase activity and the expression of telomerase components in acute myelogenous leukaemia. Br. J. Haematol. 102 (1998) 1367-1375
210. Seol J.G., Kim E.S., Park W.H., Jung C.W., Kim B.K., and Lee Y.Y. Telomerase activity in acute myelogenous leukaemia: clinical and biological implications. Br. J. Haematol. 100 (1998) 156-165
211. Trentin L., Ballon G., Ometto L., Perin A., Basso U., Chieco-Bianchi L., Semenzato G., and De Rossi A. Telomerase activity in chronic lymphoproliferative disorders of B-cell lineage. Br. J. Haematol. 106 (1999) 662-668
212. Bechter O.E., Eisterer W., Pall G., Hilbe W., Kuhr T., and Thaler J. Telomere length and telomerase activity predict survival in patients with B cell chronic lymphocytic leukemia. Cancer Res. 58 (1998) 4918-4922
213. Allshire R.C., Dempster M., and Hastie N.D. Human telomeres contain at least three types of G-rich repeat distributed non-randomly. Nucleic Acids Res. 17 (1989) 4611-4627
214. Hastie N.D., Dempster M., Dunlop M.G., Thompson A.M., Green D.K., and Allshire R.C. Telomere reduction in human colorectal carcinoma and with ageing. Nature 346 (1990) 866-868
215. Mehle C., Ljungberg B., and Roos G. Telomere shortening in renal cell carcinoma. Cancer Res. 54 (1994) 236-241
216. Slagboom P.E., Droog S., and Boomsma D.I. Genetic determination of telomere size in humans: a twin study of three age groups. Am. J. Hum. Genet. 55 (1994) 876-882
217. Yan P., Benhattar J., Coindre J.M., and Guillou L. Telomerase activity and hTERT mRNA expression can be heterogeneous and does not correlate with telomere length in soft tissue sarcomas. Int. J. Cancer 98 (2002) 851-856
218. Aida J., Izumiyama-Shimomura N., Nakamura K., Ishikawa N., Poon S.S., Kammori M., Sawabe M., Arai T., Matsuura M., Fujiwara M., Kishimoto H., and Takubo K. Basal cells have longest telomeres measured by tissue Q-FISH method in lingual epithelium. Exp. Gerontol. 43 (2008) 833-839
219. Canela A., Vera E., Klatt P., and Blasco M.A. High-throughput telomere length quantification by FISH and its application to human population studies. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 5300-5305
220. Djojosubroto M.W., Chin A.C., Go N., Schaetzlein S., Manns M.P., Gryaznov S., Harley C.B., and Rudolph K.L. Telomerase antagonists GRN163 and GRN163L inhibit tumor growth and increase chemosensitivity of human hepatoma. Hepatology 42 (2005) 1127-1136
221. Martens U.M., Zijlmans J.M., Poon S.S., Dragowska W., Yui J., Chavez E.A., Ward R.K., and Lansdorp P.M. Short telomeres on human chromosome 17p. Nat. Genet. 18 (1998) 76-80
222. Meeker A.K., Hicks J.L., Platz E.A., March G.E., Bennett C.J., Delannoy M.J., and De Marzo A.M. Telomere shortening is an early somatic DNA alteration in human prostate tumorigenesis. Cancer Res. 62 (2002) 6405-6409
223. Kimura M., Barbieri M., Gardner J.P., Skurnick J., Cao X., van Riel N., Rizzo M.R., Paoliso G., and Aviv A. Leukocytes of exceptionally old persons display ultra-short telomeres. Am. J. Physiol., Regul. Integr. Comp. Physiol. 293 (2007) R2210-2217
224. Herbert B.S., Hochreiter A.E., Wright W.E., and Shay J.W. Nonradioactive detection of telomerase activity using the telomeric repeat amplification protocol. Nat. Protoc. 1 (2006) 1583-1590
225. Hou M., Xu D., Bjorkholm M., and Gruber A. Real-time quantitative telomeric repeat amplification protocol assay for the detection of telomerase activity. Clin. Chem. 47 (2001) 519-524
226. Huang Y.P., Liu Z.S., Tang H., Liu M., and Li X. Real-time telomeric repeat amplification protocol using the duplex scorpion and two reverse primers system: the high sensitive and accurate method for quantification of telomerase activity. Clin. Chim. Acta 372 (2006) 112-119
227. Kabotyanski E.A., Botchkina I.L., Kosobokova O., Botchkina G.I., Gorfinkel V., and Gorbovitski B. Highly sensitive revealing of PCR products with capillary electrophoresis based on single photon detection. Biosens. Bioelectron. 21 (2006) 1924-1931
228. Kong D., Jin Y., Yin Y., Mi H., and Shen H. Real-time PCR detection of telomerase activity using specific molecular beacon probes. Anal. Bioanal. Chem. 388 (2007) 699-709
229. Shim W.Y., Park K.H., Jeung H.C., Kim Y.T., Kim T.S., Hyung W.J., An S.H., Yang S.H., Noh S.H., Chung H.C., and Rha S.Y. Quantitative detection of telomerase activity by real-time TRAP assay in the body fluids of cancer patients. Int. J. Mol. Med. 16 (2005) 857-863
230. Wege H., Chui M.S., Le H.T., Tran J.M., and Zern M.A. SYBR Green real-time telomeric repeat amplification protocol for the rapid quantification of telomerase activity. Nucleic Acids Res. 31 (2003) E3-3
231. Elmore L.W., Forsythe H.L., Ferreira-Gonzalez A., Garrett C.T., Clark G.M., and Holt S.E. Real-time quantitative analysis of telomerase activity in breast tumor specimens using a highly specific and sensitive fluorescent-based assay. Diagn. Mol. Pathol. 11 (2002) 177-185
232. Yi X., White D.M., Aisner D.L., Baur J.A., Wright W.E., and Shay J.W. An alternate splicing variant of the human telomerase catalytic subunit inhibits telomerase activity. Neoplasia 2 (2000) 433-440